TG6-10-1

Research use only, not for human use.

TG6-10-1 is an EP2 antagonist.

TG6-10-1 is a potent and selective antagonist for the prostaglandin E2 receptor subtype EP2. Systemic administration of TG6-10-1 completely recapitulates the effects of conditional ablation of cyclooxygenase-2 from principal forebrain neurons, namely reduced delayed mortality, accelerated recovery from weight loss, reduced brain inflammation, prevention of blood-brain barrier opening, and neuroprotection in the hippocampus, without modifying seizures acutely. TG6-10-1 shows low-nanomolar antagonist activity against EP2.

TG6-10-1 robustly blocks prostaglandin E2 (PGE2) (10 μM)-induced cAMP accumulation in a concentration-dependent manner in SH-SY5Y cells.

TG6-10-1 (5 mg/kg; i.p.; 4-30 hours) improves survival, accelerates recovery of lost weight, and improves functional recovery following status epilepticus (SE) . Animal Model:C57BL/6 mice (pilocarpine-induced SE)Dosage:5 mg/kg Administration:Intraperitoneal injection; 4, 21, 30 hours Result:A significant increase in survival and accelerating the recovery of lost weight in post-SE mice.

TG6-10-1 | TG 6-10-1 | TG-6-10-1 | TP6101

PI3K/Akt/mTOR signaling

PI3K

5-HT2B

Neurological Disease

——

1415716-58-3

448.43

C23H23F3N2O4

>98% (HPLC)

DMSO : ≥ 100 mg/mL; 223.00 mM

C(=O)(/C=C/c1cc(c(c(c1)OC)OC)OC)NCCn1c(cc2ccccc12)C(F)(F)F

(E)-N-(2-(2-(trifluoromethyl)-1H-indol-1-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide

(-20℃)

With Ice Pack

≥ 2 years